Axonal transport defects in a mitofusin 2 loss of function model of Charcot-Marie-Tooth disease in zebrafish

AL Chapman, EJ Bennett, TM Ramesh, KJ De Vos… - PloS one, 2013 - journals.plos.org
AL Chapman, EJ Bennett, TM Ramesh, KJ De Vos, AJ Grierson
PloS one, 2013journals.plos.org
Charcot-Marie-Tooth disease (CMT) represents a group of neurodegenerative disorders
typically characterised by demyelination (CMT1) or distal axon degeneration (CMT2) of
motor and sensory neurons. The majority of CMT2 cases are caused by mutations in
mitofusin 2 (MFN2); an essential gene encoding a protein responsible for fusion of the
mitochondrial outer membrane. The mechanism of action of MFN2 mutations is still not fully
resolved. To investigate a role for loss of Mfn2 function in disease we investigated an ENU …
Charcot-Marie-Tooth disease (CMT) represents a group of neurodegenerative disorders typically characterised by demyelination (CMT1) or distal axon degeneration (CMT2) of motor and sensory neurons. The majority of CMT2 cases are caused by mutations in mitofusin 2 (MFN2); an essential gene encoding a protein responsible for fusion of the mitochondrial outer membrane. The mechanism of action of MFN2 mutations is still not fully resolved. To investigate a role for loss of Mfn2 function in disease we investigated an ENU-induced nonsense mutation in zebrafish MFN2 and characterised the phenotype of these fish at the whole organism, pathological, and subcellular level. We show that unlike mice, loss of MFN2 function in zebrafish leads to an adult onset, progressive phenotype with predominant symptoms of motor dysfunction similar to CMT2. Mutant zebrafish show progressive loss of swimming associated with alterations at the neuro-muscular junction. At the cellular level, we provide direct evidence that mitochondrial transport along axons is perturbed in Mfn2 mutant zebrafish, suggesting that this is a key mechanism of disease in CMT. The progressive phenotype and pathology suggest that zebrafish will be useful for further investigating the disease mechanism and potential treatment of axonal forms of CMT. Our findings support the idea that MFN2 mutation status should be investigated in patients presenting with early-onset recessively inherited axonal CMT.
PLOS